Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standal
| Current Price | ₹541.50 |
|---|---|
| Market Cap | ₹11,227 Cr |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Laboratory Services |
| P/E Ratio | 58.9 |
| Return on Equity | 13.37% |
| 52-Week Range | ₹411.25 – ₹600.00 |
| Beta (1Y) | 0.7 |
| Dividend Yield | 0.37% |
1. Pathology Service-100%
Metropolis Healthcare Limited is trading at ₹541.50, with a market capitalisation of ₹11,227 Cr.
Metropolis Healthcare Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Laboratory Services).
Metropolis Healthcare Limited has a P/E of 58.9 and a return on equity of 13.37%.